blood culture collection News
-
Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System
Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. The Advance Safety Needle System was tested in 2021 and is now being sold into accounts using Kurin. “We are proud to commercialize the Advance Safety Needle, as there ...
By Kurin, Inc.
-
Kurin, Inc. announces UK clinical study results showing significant decrease in blood culture contaminations with the Kurin Lock™
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today a new clinical study supporting the efficacy of their blood culture collection product. Authors from Guy’s and St. Thomas’ NHS Foundation Trust, a prestigious London-based hospital, presented their data at the recent Infection Prevention Society conference in ...
By Kurin, Inc.
-
Kurin, Inc. Announces Removal of Magnolia Patent Infringement Lawsuit Trial Date
Kurin Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced that the U.S. District Court in Delaware has removed the trial date from the docket in the patent-infringement lawsuit brought against Kurin by Magnolia Medical. The Court indicated that, if necessary, it will provide a trial date after it decides motions for summary judgment. This delay followed ...
By Kurin, Inc.
-
Kurin, Inc. Named to Inc.’s Inaugural Best in Business List in the Prosperous and Thriving Category
Kurin, Inc. has been named to Inc.’s inaugural Best in Business list in the Prosperous and Thriving category. Inc. created the Best in Business Awards to honor companies that have gone above and beyond to make a positive difference. The list, which can be found in the Winter issue of Inc. (on newsstands December 29, 2020), recognizes small- and medium-size privately held American ...
By Kurin, Inc.
-
Kurin, Inc. announces results on Kurin efficacy from Oishei Children`s Hospital with zero blood culture
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a passive low-volume blood culture ...
By Kurin, Inc.
-
Kurin, Inc. announces peer-reviewed publication on Kurin® efficacy from Central Texas Veterans Health Care System
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the Central Texas VA Health Care System in Temple, TX, published their findings comparing results of two devices: Kurin and Steripath® (Magnolia Medical Technologies, Inc.) in the online edition of the Journal of Emergency Nursing. This is the first peer-reviewed ...
By Kurin, Inc.
-
Magnolia Medical, MHA Solutions, and Healthcare Providers Insurance Company Enter into an Exclusive, Endorsed Agreement for the Steripath Initial Specimen Diversion Device
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 announced today that it has entered into an endorsed company agreement with MHA Solutions, a subsidiary of the Mississippi Hospital Association (MHA), and Healthcare Providers Insurance (HPIC), a reciprocal insurer that ...
-
Magnolia Medical Announces Expansion of Its Extensive Clinical Evidence Library with Six Steripath® ISDD® Studies in 2021 Demonstrating Zero or Near-Zero False Positive Sepsis Test Results
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced that six studies, reporting zero or near-zero blood culture contamination rates and up to a 31% reduction in vancomycin days of therapy (DOT) using Steripath, were submitted, accepted and published in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you